Karyopharm Therapeutics financials
$1.21−25.62%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $146.1M | $145.2M | $146.0M | $157.1M | $209.8M | $108.1M | $40.9M | $30.3M | $1.6M | $154.0K |
| Gross profit | $140.1M | $139.2M | $141.1M | $151.9M | $206.4M | $105.4M | $40.9M | $30.3M | $1.6M | $154.0K |
| Gross margin | 95.9% | 95.9% | 96.6% | 96.7% | 98.4% | 97.5% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$90.7M | -$119.4M | -$129.5M | -$142.2M | -$98.3M | -$171.8M | -$189.3M | -$179.9M | -$130.5M | -$110.7M |
| Net income | -$196.0M | -$76.4M | -$143.1M | -$165.3M | -$124.1M | -$196.3M | -$199.6M | -$178.4M | -$129.0M | -$109.6M |
| Net margin | −134.2% | −52.6% | −98.0% | −105.2% | −59.1% | −181.6% | −488.1% | −588.1% | −8036.4% | −71153.9% |
| Diluted EPS | $-17.93 | $-14.00 | $-18.79 | $-30.30 | $-24.75 | $-40.80 | $-48.30 | $-47.10 | $-42.15 | $-43.80 |
| EBITDA | -$90.4M | -$119.1M | -$129.0M | -$141.6M | -$97.5M | -$170.9M | -$188.3M | -$179.1M | -$129.8M | -$110.0M |
| Operating cash flow | -$75.4M | -$127.5M | -$92.7M | -$149.6M | -$107.1M | -$160.2M | -$190.8M | -$159.1M | -$73.7M | -$84.4M |
| Free cash flow | -$75.4M | -$127.6M | -$92.7M | -$149.7M | -$107.3M | -$160.4M | -$191.0M | -$161.5M | -$73.8M | -$84.5M |
| Diluted shares | 10.9M | 8.5M | 7.6M | 5.5M | 5.0M | 4.8M | 4.1M | 3.8M | 3.1M | 2.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $60.5M | $62.5M | $52.2M | $135.2M | $190.5M | $85.9M |
| Short-term investments | $3.2M | $46.2M | $139.2M | $142.8M | $38.2M | $163.3M |
| Total debt | $226.9M | $187.4M | $170.9M | $170.1M | $169.3M | $117.9M |
| Total assets | $108.4M | $164.4M | $240.4M | $358.2M | $305.3M | $313.1M |
| Total liabilities | $401.3M | $350.4M | $376.6M | $374.8M | $385.0M | $262.5M |
| Shareholders' equity | -$292.9M | -$186.0M | -$136.2M | -$16.7M | -$79.7M | $50.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology